Following on from information provided to NICE by the company in March 2021, the appraisal of Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1561 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 21 November 2022 | Following on from information provided to NICE by the company in March 2021, the appraisal of Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 21 November 2022 | Discontinued. Following on from information provided to NICE by the company in March 2021, the appraisal of Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 06 April 2021 | Suspended. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 29 July 2020 | Following on from advice received from the company the timelines for this appraisal are to be confirmed and further information regarding the scheduling of this appraisal will be available in due course. |
| 27 May 2020 - 24 June 2020 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 13 February 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual